Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Renal Cell Carcinoma
What would you recommend as first line therapy for metastatic chromophobe RCC?
Related Questions
How would you approach the use of bevacizumab in metastatic FH-deficient RCC/HLRCC that is c/b extensive IVC tumor thrombus and DVT/PE?
Is there still a role for mTOR inhibitors in metastatic RCC in the immunotherapy/TKI era?
How would you approach adjuvant systemic therapy for an isolated, oligometastatic CNS recurrence of RCC that was treated with SBRT?
If the patient has had prior partial nephrectomy for RCC, would you consider SBRT for a contralateral RCC?
Would you offer adjuvant immunotherapy in a patient with high risk RCC with new/worsening post-op renal dysfunction and CrCl<30?
What is your treatment approach in localized RCC with VHL mutation after progression on belzutifan?
How would you treat a patient with metastatic RCC with high grade neuroendocrine and sarcomatoid features after progression on IO + TKI?
Would you use adjuvant pembrolizumab for bilateral ccRCC with R1 resection?
Would the occurrence of obvious tumor rupture/spillage intraoperatively impact your decision for adjuvant systemic therapy after resection of either clear cell RCC or papillary RCC?
When, if ever, would you re-challenge with immunotherapy for patients with metastatic RCC?
